How does cytidine deaminase (CDD) affect gemcitabine efficacy?
Label:chem
Topic
Cytidine deaminase (CDD) is an enzyme that can degrade gemcitabine, a key chemotherapeutic agent used in pancreatic cancer treatment. The presence of CDD in bacteria can lead to gemcitabine resistance.
Answer
CDD enzymes, particularly the long isoform (CDDL) and short isoform (CDDS), can metabolize gemcitabine into its non-toxic metabolite, 2′,2′-difluorodeoxyuridine (dFdU). This metabolic conversion reduces the cytotoxicity of gemcitabine, leading to chemoresistance in pancreatic cancer cells. The study shows that both CDDL and CDDS can degrade gemcitabine, although the efficiency may vary depending on the bacterial strain.
Return to Home
Chemical List
Knowledge you may be interested in